
FDA Grants Approval to Pfizer’s BEQVEZ™: A Single-Dose Gene Therapy for Hemophilia B in Adults
Today, Pfizer Inc. (NYSE: PFE) announced the approval of BEQVEZ™ (fidanacogene elaparvovec-dzkt) by the U.S. Food and Drug Administration (FDA) for the treatment of adults grappling with moderate to severe hemophilia B. This approval is particularly significant for individuals currently…